<DOC>
	<DOCNO>NCT01018667</DOCNO>
	<brief_summary>The ADOPT study prospective , nested case-controlled open label clinical trial . About 40 center across China participate study plan 800 Chinese case enrollment . All patient receive optimal medical treatment . Patients successful CRT-P/D implant assign CRT group . According baseline evaluation , match case select enrolled OPT ( optimal medical treatment ) alone group ( Group Selection ) . After successful match , case Group Selection enter follow-up become control group . The unmatched case Group Selection remove . If patient agree , re-evaluation baseline situation , may enter Group Selection . Since patient know she/he already device implant examiner aware group patient see incision scar post-implant electrocardiogram , study open-label design , however executive committee keep blind make event-adjudication . Prospectively define primary end point study include combine all-cause mortality hospitalization . A variety secondary end point define efficacy mechanism ( ) action cardiac resynchronization heart failure . The last date study shall day 24 month follow-up last enrolled patient . All case collection complete 2010 study result report 2012 .</brief_summary>
	<brief_title>Assessment Efficacies Cardiac Resynchronization Therapies ( CRT-P/D ) Heart Failure Patients China</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Heart failure patient must meet criteria:1.ischemic nonischemic cardiomyopathy ; 2.NYHA class IIIIV despite OPT ; 3.normal sinus rhythm ; 4.LVEF≤35 % ; 5.LV enddiastolic diameter≥55mm ; 6.Wide QRS complex≥120ms . 1.Potentially reversible form cardiomyopathy ; 2.Cardiac surgery , percutaneous coronary intervention , cardiomyoplasty , myocardial infarction , unstable severe angina stroke within 6 week randomization ; 3.Inpatients require continuous intravenous therapy heart failure ; 4.Life expectancy &lt; 1 year disease unrelated heart failure ; 5.Mechanical tricuspid valve ; 6.Anticipated problem compliance ; 7.Participation another trial ; 8.Age &lt; 18 year old ; 9.Women pregnant use medically acceptable birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>clinical trial</keyword>
	<keyword>biventricular pacing</keyword>
	<keyword>cardiac device</keyword>
</DOC>